Assembly Bio has discontinued development of ABI-H2158, its candidate to treat hepatitis B, after observing elevated levels of alanine transaminase (ALT) — a sign of liver toxicity — in Phase II patients, the biotech said Wednesday.
Recall: Baxter`s Clinimix (2015-06-19)